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INTRODUCTION
Since the development of the first specific antibody
producing hybrid cells in 1975, monoclonal antibodies have
become sophisticated and very practical research tools that
are presently being employed by a large number of
biological research laboratories. This report attempts to
describe the advancements that have been made in monoclonal
antibody technology in the past decade and to discuss one
of the most recent utilizations of monoclonal antibodies,
cancer therapy.
Predominantly, however, monoclonal antibodies are used
as a method to purify and characterize specific biological
proteins. Our laboratory has isolated, from bovine
cerebral cortex cells, an 18 kD sialoglycopept ide growth
regulator which inhibits cellular protein and DNA
synthesis. We have characterized three monoclonal
antibodies directed against this growth inhibitor which
will eventually enable the rapid purification of the
sialoglycopept ide or its parental molecule and allow for
the detection of the protein on a variety of cell surfaces.
Additionally, these monoclonal antibodies were useful in
demonstrating that the s ialoglycopept ide is unique from
other presently studied growth regulators such as p* -
transforming growth factor and fibroblast growth regulator
and can be depicted as a novel cell growth inhibitor.
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DEVELOPMENTS IN MONOCLONAL ANTIBODY TECHNOLOGY
Antibodies are a very important part of the immune
system as they have the ability to specifically locate and
bind to any ligand which is not recognized as "self." It
has been known for decades that introducing a foreign
substance or antigen into the body would elicit an
antibody response. Antibodies resulting from such
responses were found to be present in the sera extracted
from animals "immunized" with a particular antigen. These
antibodies became useful tools in the laboratory for
antigen detection and localization. However, it was
evident that sera from immunized animals contained many
antibodies directed against other antigen; indeed,
antibodies against the desired antigen were of various
classes and specificities. This launched the search for
methods to obtain substantial quantities of one very
specific antibody that would be directed against a single
epitope of an antigen. In 1975, Kohler and Milstein (45)
published a paper which established the groundwork for the
future production of monoclonal antibodies. Their research
was based on the observation that only one type of antibody
was produced by cloned lymphocytes which had been
stimulated by a particular antigen, and that fused cells
from two myeloma cell lines resulted in hybrid cells that
synthesized the antibody of each lymphocyte parental cell
(8,65). Utilizing Sendai virus, which promoted the fusion
of cell membranes, they were able to produce hybridomas
from immunized Balb/c spleen cells and a compatible Balb/c
myeloma cell line. These hybrids survived in culture and
secreted antibodies to sheep red blood cell antigen. Many
laboratories soon began to capitalize on the innovative
research of Kohler and Milstein.
The next few years saw an explosion of monoclonal
antibody technology. For example, improvements were made
in the procedures for cell fusion. Sendai virus
was replaced by high molecular weight polyethylene glycol
as a fusing agent (14,16). which allowed for a greater
percentage of hybridoma survival and growth (73). The next
improvement came with the development of a Balb/c myeloma
cell line that did not secrete antibody prior to cell
fusion. P3-X67Ag8 myeloma cells, used for the Kohler and
Milstein experiments, produced IgGKk) antibodies.
Hybridomas with these cells and Balb/c lymphocytes secreted
not only the desired fusion product, derived from both
parental cells, but the P3-X67Ag8 myeloma protein as well.
With random association of antibody producing genes from
both parental cells, the desired specific antibody would
make up only 1/16 of the total immunoglobulins produced by
the hybridomas (73). Therefore, the "non-secreting" Balb/c
myeloma cell line Sp 2/0-Agl4 was developed (73) although
fusion efficiency with this myeloma cell declined as
compared to fusions with P3-X67Ag8. One year later (1979),
subclones of P3-X67Ag8 cells were isolated that had lost
immunoglobulin expression (40). Fusion efficiency again
increased to its previously reported level and the
resulting hybrid cells produced pure monoclonal antibodies.
The new myeloma cell line was designated X63-Ag8.653 and is
the most widely used myeloma line for present
hybridization.
It would be impractical to mention every technological
advance which has led to the present understanding of
monoclonal antibody development. However, in 1980, Fazekas
de St. Groth and Scheidegger (14) published a review
article on the strategy and tactics of the production of
monoclonal antibodies which was instrumental in
establishing a means of increasing cell fusion efficiency
and clonal stability. They examined the effect of
macrophages as a feeder layer for the proliferating
hybridomas. A striking increase in the number of culture
wells with growing hybrids was observed when macrophages
were introduced to the hybridoma cultures. Hybridomas are
autotrophic and the addition of macrophages may have
conditioned the selective medium which sustained hybrid
vigor and growth. Another benefit of macrophages was their
ability to "clean-up" culture wells of bacteria and
cellular debris. The optimization of the ratio of spleen
cells to myeloma cells that were used during cell fusion
was also considered. Most previous hybridizations were
carried out using a ten fold excess of spleen cells to
myeloma cells. This ratio favored the production of
spleen/spleen hybrids which would not survive
in culture. Adding a lower number of spleen cells than
myeloma cells, however, increased the possibility of a
desired fusion product (14). Fusion efficiency and
hybridoma survivability and stability are still being
extensively studied and improved.
Another change that occurred which remains a part of
present techniques was the development of sophisticated
assays to detect the presence of monoclonal antibodies in
hybridoma culture media. Earliest methods utilized simple
plaque assays for antibody detection, as the majority of
monoclonal antibodies produced were directed toward large
immunogens such as sheep red blood cells (45). However,
antibodies produced against non-cellular antigens required
the use of radioimmunoassays or enzyme linked
lmmunoabsorbent assays for antibody detection, both of
which serve this purpose. Recently, though, there have
been two major advances in monoclonal antibody technology;
the hybridization of spleen cells which have been immunized
iu y.i£E2 thus eliminating the time involved in the initial
pristine priming, injecting and screening of the mouse (29,
52) and the development of hybridomas using spleen cells
from a Robertsonian mouse strain (81) which warrants a more
detailed description.
Monoclonal antibody production thus far had dealt with
improvements of the tissue culture involved in growing
hybridomas. Unfortunately, the fact that hybridomas
randomly discard important chromosomes during proliferation
was a problem that always hampered hybrid stability (53).
In 1983, Taggart and Samloff (76) focused directly on
improving the genetics of monoclonal antibody production.
Initial studies by Taggart and Samloff showed that the
selective media used to sustain hybridoma growth was
important for stability. Hypoxanthine, aminopterin, and
thymidine (HAT) media, which is a standard hybrid media,
preferentially selects for hybrids with the HPRT
(hypoxanthine phosphor ibosyl transferase) gene located on
the X chromosome of spleen cells. The gene coding for the
active heavy chain of the immunoglobulin, though, is
located on chromosome 12. Antibody producing hybridomas
that discard the X chromosome, therefore, are eliminated by
the HAT selection process (51). In a system such as
monoclonal antibody production where the probabilities of
obtaining cells secreting the desired monoclonal antibody
are extremely variable, this event could be detrimental,
Taggart and Samloff hybridoma technology involves adenine,
aminopterin, and thymidine (AAT) selective culture media
which destroys hybrids that do not contain the APRT
(adenosine phosphor ibosyl transferase) gene. This gene is
located on chromosome 8. AAT as an alternative selective
media becomes useful when the spleen cells used for cell
fusion are from the RBF/Dn strain of mice. These mice
carry the Robertsonian 8.12 translocation chromosome. In
this system, the genetic information for the immunoglobulin
active heavy chain has been translocated from chromosome 12
to chromosome 8 which now also carries the immunoglobulin
gene, thus decreasing the possibility of non-producing
hybridoma culture.
In the past decade, the development of monoclonal
antibodies has been one of the most valuable assets to
modern research. Such a versatile laboratory tool carries
the promise of more novel and exciting research in the near
future
.
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CANCER IMMUNOTHERAPY UTILIZING MONOCLONAL ANTIBODIES
The idea of therapeutically exploiting antibodies
directed against tumor cell surfaces is not a new concept.
It was proposed as early as 1906 (11). Because of antibody
specificity and cytotoxicity, they provided an appealing
approach to cell destruction in y.iy.0.. With the advent of
hybridoma technology (45) unlimited quantities of pure,
homogeneous monoclonal antibodies of defined specificity
could be produced, thus heightening the potential for
antibody therapy. In recent years immunotherapy has
gained notoriety in the treatment of cancer and research
has been conducted utilizing techniques involving
monoclonal antibodies.
Presently, many articles have been published reporting
the production of monoclonal antibodies directed against
antigens associated with various types of cancer cells and
cell lines such as melanomas (30,46), carcinomas (23,50),
neuroblastomas (20,42), sarcomas (12,33), and leukemias
(17,61). Therapeutically, these types of antibodies have
been used in clinical trials, alone and in the presence of
complement, as a means of tumor cell eradication. For
example, serotherapy, with monoclonal antibodies directed
against leukemia or T cell lymphoma antigens (anti-Leu-1)
(54), has shown in many studies to clear neoplastic cells
from the blood of patients, at least temporarily (10,55,
59,62). Additionally, complete tumor remission has been
observed lasting more than six months after therapy when a
patient was given monoclonal antibodies directed against an
idiotypic determinant of a B cell lymphoma (56). However,
treatment involving the use of a single monoclonal antibody
may not be significantly cytotoxic In some cases.
Therefore, more than one antibody may be used in
conjunction with others to treat a cancer. Effective
target cell killing was achieved when antibodies to two
epitopes of p97, a human melanoma-associated antigen,
reacted synergist ical ly against melanoma cells in jMtro,
whereas neither antibody alone was significantly cytotoxic
(27). This synergistic effect also allowed for the use of
antibody concentrations of only 2 ng/ml, lower than
required dosages for single antibody treatments (27).
Interestingly, the synergistic effect was only observed in
the presence of a heterologous serum as a source of
complement. This creates obvious immunological problems
when administered j.n y.iy.2-
Although monoclonal antibodies have been used alone
for cancer immunotherapy, they can also be employed as
carriers of anti-tumor agents. At least four types of
anti-tumor agents can be conjugated to antibodies and these
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are: radioisotopes, chemotherapeut ic agents, immune
response modifiers and toxins (28). First, antibody, Fab
or F(ab' ) fragments, can be labeled with a radioisotope so
as to deliver a toxic dose of radiation to the tumor (39).
This may be with a beta emitter such as m I (47) or a
gamma emitter like 125 I. Unfortunately, it has been
discovered that the amounts of radiolabeled tumor
associated monoclonal antibodies reaching their target
tissues after i.v. administration are sometimes too small
to be exploited therapeutically (13). However, these
radiolabeled probes do provide an excellent means of
identifying and imaging tumor tissue (9,25,47).
Secondly, conjugates of monoclonal antibody and
chemotherapeut ic drugs such as chorambucil, daunomycin or
adriamycin have been prepared (18,35) although studies
with these conjugates, being utilized for treatment £n
Y.iy.£> have not been published.
A third conjugate which shows therapeutic potential is
antibody and a molecule that induces a local delayed-
hypersensitivity reaction within the tumor. This conjugate
would cause an anti-tumor reaction analogous to that
achieved by applications of dinitrochlorobenzene over a
skin carcinoma (3) or when B cell growth factor (BCG) is
injected into a melanoma nodule (57). Again, no published
11
information can be found regarding the actual use of this
conjugate in therapy.
Of all the previously mentioned means of incorporating
monoclonal antibodies as a tool in immunotherapy, the most
researched and published method is the fourth conjugate,
immunotoxlns, which warrant a discussion of more depth. In
this conjugate, monoclonal antibodies are linked by
chemical reduction of the disulfide bonds of toxin A chain
subunits, which result in a thiol group that can be linked
to IgG or IgM antibodies by disulfide exchange reaction and
average approximately one or two toxin molecules per
Immunoglobulin (15). Examples of toxins that are
conjugated to antibodies are: plant hemitoxins such as
pokeweed antiviral protein (36), plant toxins which include
ricin (60) and bacterial toxins like diphtheria toxin (64).
Ricin, however, appears to be the toxin of choice for most
conjugates. In particular, one ricin immunoconjugate, WTI-
RTA, directed against T-ALL tumor antigens, demonstrates a
ten-fold increase in therapeutic index over other existing
conjugates (58) where the therapeutic index is the
concentration of immunotoxin required to kill 50% of tumor
cells.
Immunotoxlns are usually very potent and kill human
tumor cells at ng/ml concentrations (1,67). In y.ilr.2
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efficacies of immunotoxins have been established using
standard test systems including protein synthesis
inhibition and colony inhibition assays carried out on
clonogenic cell lines (6,48). However, of particular
interest, is the research performed dealing with
immunotoxin efficacy j.n vivo. Weil-Hillman e.t gl . (79)
have recently demonstrated that 86% of r icin- immunotox in
treated nude mice appeared to have complete tumor
regression. It is important, though, to state that
treatment with this immunotoxin was accompanied by the
cyclophosphamide congener, mafosfamid which aided killing
efficiency and persistent tumor regression. Clinical
applications of immunotoxins in human cancer patients have
been primarily £2 y.iy.2 studies depleting autologous bone
marrow grafts of tumor cells in leukemia and lymphoma
patients. Ramsey £t a.1^ <15) used two anti-T-cell antibody
ricin conjugates on six leukemla/lymphoma patients who had
been conditioned with cyclophosphamide and total body
irradiation. Two of these patients were considered
disease-free three and eleven months post-transplantation
of treated bone marrow.
Studies much like those previously mentioned using
immunotoxins are becoming more prevalent. However, like
other forms of cancer treatment, the use of monoclonal
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antibodies in immunotherapy has many limitations which must
be mentioned. The major problem facing this therapy Is the
lack of a tumor specific cell surface antigen. Many
antibodies are directed against tumor antigens but these
may also be associated with non-neoplast lc cells as well.
A second shortcoming is that although mouse monoclonal
antibodies alone may not be cytotoxic to humans, the
chemotherapeut ic drug or toxin conjugated to the antibody
causes very serious side effects. Third, even though most
cancer patients have had diseases or other treatments that
could impair their immunocompetence , more than 50% make
significant antibody responses against the foreign
therapeutic antibody (49). Finally, other obstacles
include antigenic modulation, free antigen blockade and
immunoselect ion.
Although the actual use of therapeutic antibodies is
still a very recent event, much research has been
accomplished in this area. Eventually a tumor specific
antigen may be discovered. Human-human hybridomas have
already been produced. These two events, and the advent of
more sophisticated technology, will further enhance
immunotherapy.
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THE BOVINE SIALOGLYCOPEPTIDE INHIBITOR
Most mammalian cells exist in two physiological
states: quiescent and proliferative, which are regulated
by various stimulators and inhibitors. Research in the
past decade has led to the understanding of the structure
and function of polypeptide growth factors that produce
cellular proliferation (19,26,37,41). However, much less
progress has been made in the study of cell growth
inhibitors. The isolation of inhibitors from various cell
surfaces has recently been reported (32,66,75,80) but
purification to homogeneity and extensive characterization
has not yet been demonstrated with many of these
inhibitors. One such inhibitor which has been purified and
partially characterized, though, is the bovine cerebral
cortex cell surface sialoglycopept ide
.
The bovine growth inhibitor which is presently being
studied was removed from cerebral tissue by a mild pronase
treatment followed by ethanol precipitation and
chloroform/methanol extraction of the macromolecules (71).
This crude preparation was then purified by DEAE ion
exchange chromatography and wheat germ agglutinin affinity
chromatography. Final purification was by size exclusion
and hydroxylapatite HPLC (2). This extensive purification
procedure yielded a homogeneous sialoglycopept ide with a
15
'molecular weight of approximately 18 kD and a pi of 3.0 as
determined by SDS-PAGE and isoelectric focusing analyses,
respectively (72). Other growth Inhibitors from chick
embryo fibroblasts and bovine mammary gland have only been
partially purified (5,82). However, many other inhibitors
have been extracted from the conditioned medium of various
primary and established cell lines (24,32,34,80) while yet
another is considered to be a protein purified from murine
serum (21,22).
Initial studies which eventually led to the isolation
of the sialoglycopept ide from bovine brain cells, conducted
by Kinders §.£ al.. (44), described the characterization of
glycopeptides from mouse cerebral cortex that inhibited
cell growth and protein synthesis. However, the method of
isolation and the small amount of cortical tissue that
could be removed from a mouse brain limited the supply of
inhibitor to minute quantities (5 ug/200 cerebral
cortices). Utilizing the bovine brain and a revision of
the initial purification procedure, led to production of ug
quantities of inhibitor from a single preparation. This
material also had a specific activity 46 times greater than
the earlier mouse-derived inhibitor (38,44,72).
The growth inhibitory activity of the
sialoglycopeptide has been determined to be due to
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inhibition of cellular protein and DNA synthesis of
specific types of cells (43,72). This activity is not
cytotoxic and is readily reversible, traits characteristic
of growth inhibitors (78). Specific activity of the
s ialogl ycopept ide
, as measured by protein synthesis
inhibition, has been reported as 100,000 units/mg protein
where 1 unit (50 ng) is equivalent to 25% inhibition. This
specific activity is relatively high as compared to, for
example, the mouse embryo fibroblast inhibitor protein
purified by Wells and Malluccl which requires 30-50 ug of
inhibitor protein to produce equivalent inhibition
(80). Although the s ialoglycopept ide is an effective
inhibitor of protein and DNA synthesis of normal cells, its
inhibitory activity also blocks proliferation of a wide
variety of transformed cells. Notably, all growth
inhibitors presently studied are derived from cells that
are density-dependent growth arrested. It is logical to
assume that density-independent cells would not react to
the inhibitory effect of the s ialoglycopept ide . However,
at least two other inhibitors appear to inhibit the growth
of mammary carcinoma cells (4,31) and a neuroblastoma cell
line (66).
The sialoglycopeptide inhibitor isolated from bovine
cerebral cortex cells, is a potent inhibitor of cell
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division of a wide variety of cells Isolated from diverse
species. Nanogram quantities arrest DNA synthesis of
bovine, mouse, rat, human, and even insect species.
Associated with the s ialoglycopept ide is a protease
activity which cannot be physically separated during
purification of the inhibitor to homogeneity and is not a
direct result of the purification process (68). This
protease activity is unique as it could not be inactivated
by a battery of protease inhibitors. Gundersen et al. (21)
have recently Isolated an inhibitory factor from mouse sera
that has protease activity. However, this protease could
be deactivated by a serine protease inhibitor.
Additionally, the protease activity was demonstrated to be
necessary for growth inhibition from the mouse sera
inhibitory factor. This is not the case for the
sialoglycopept lde . A second unique property of the
slaloglycopept ide is its ability to agglutinate transformed
or nontransf ormed cells in solution (74). Although the
agglutination reaction of the sialoglycopept ide appears
to be discrete from its biological inhibitory activity, the
protease activity, associated with the s ialoglycopept ide,
could be responsible for agglutination at the cell surface
(74).
To date, published literature on growth inhibitors is
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lacking information as to the mode of action of inhibitory
molecules. Initial experiments to determine the
interaction of the s ialoglycopept ide with its target cells
have shown, however, that specific receptors for the
sialoglycopept ide exist on target cell surfaces and that
there is a direct correlation between receptor occupancy
and the inhibition of protein synthesis by the
sialoglycopept ide (2). Additionally, Sharifi §.£ a.1. <69)
have demonstrated that this cell surface interaction is
sufficient for the biological activity of the
sialoglycopept ide. It can be concluded that the
sialoglycopeptide does not have to be internalized to
inhibit cell proliferation. This information suggests that
inhibition may be carried out by a second messenger. It
has been shown that the inhibitory activity of the
sialoglycopeptide, when bound to its receptor, is
antagonized by the calcium ionophore A23187 but not by the
sodium ionophore Monensin (70). Therefore, the
sialoglycopeptide may have an influence on calcium ion
flux, intracellular calcium availability, or subsequent
cellular metabolic events that lead to inhibition of
protein and DNA synthesis (70). However, the exact nature
of the sialoglycopept ide's mode of action and its
relationship to calcium ions has yet to be established.
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Many Interesting aspects of the sialoglycopept ide and
its biological activity are still awaiting further
investigation. Primary experiments have been initiated to
identify and characterize the s ialoglycopept ide ' s target
cell receptor. Gangliosides G
M1 , GDlj , and G^ have been
eliminated as possible receptors (co-receptors) for the
s ialoglycopept ide . Ant
i
idiotypic monoclonal antibodies may
eventually prove useful for receptor characterization.
Additionally, monoclonal antibodies have already
been utilized in studies aimed at comparing the
sialoglycopept ide with other growth inhibitors to determine
structural homologies. This is an important concept as
recently it has been reported that (3 -transforming growth
factor, a growth regulator with a bifunctional role of
inhibition and stimulation (63), is closely related or
identical to the BSC-1 growth inhibitor described by Holley
et al. (32,77). Although the s ialoglycopept ide is not
structurally related to p* -transforming growth factor or
fibroblast growth regulator (75), further investigations
with other inhibitors are warranted (see manuscript). A
final Interesting aspect of the sialoglycopept ide that
needs further study is the cell cycle phase in which cell
growth is arrested. Recent observations have indicated
that cell growth arrest was occurring In the phase Gl
(7,72).
20
Obviously, the s ialoglycopept ide Is a very intriguing
molecule. Studies of the s ialoglycopept ide and other
growth inhibitors as previously discussed, however, will
lead to a better understanding of negative regulation of
cell growth.
21
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CHARACTERIZATION "OF THREE MONOCLONAL ANTIBODIES
DIRECTED AGAINST A BOVINE CEREBRAL CORTEX CELL
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ABSTRACT
Three monoclonal antibodies, G4, G8 and F10, have been
produced and are directed against an 18 kD bovine cerebral
cortex cell surface sialoglycopept ide that inhibits cell
proliferation and metabolism by blocking the synthesis of
DNA and protein molecules. Characterization of these
monoclonal antibodies has demonstrated that all three
antibodies are of the IgGl subclass and similarily, all of
the antibodies bind to the biologically active polypeptide
backbone of the sialoglycopept ide . However, the monoclonal
antibodies did not react slmilarlly when tested for their
ability to neutralize the biological activity of the
sialoglycopept Ide . G4 could not block the protein
synthesis inhibitory activity whereas G8 and F10 were
effective. Upon autohydrolysls of the sialoglycopept ide's
protein structure (4 fragments), G8 monoclonal antibody was
shown to compete more efficiently for the largest molecular
weight fragment. The monoclonal antibody, G8, was also
utilized as a tool to compare the s ialoglycopept ide with
other growth inhibitors presently being studied. It was
determined that the s ialoglycopept ide contains a region in
its amino acid sequence which appears to be unique from
fibroblast growth regulator and -transforming growth
factor.
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INTRODUCTION
It is now well established that regulation of cell
growth involves a complex interaction between growth
inhibitors and growth factors (11,21). Various growth
factors have been isolated and the interactions of these
growth factors with their respective target cells have been
investigated in great detail (9,15). There is, however,
little information available on the interaction of growth
inhibitors. The primary reason for this lack of knowledge
concerning growth inhibitors is the difficulty in the
purification of these hydrophobic molecules. Our
laboratory has purified to homogenlety and partially
characterized a bovine cerebral cortex cell surface
sialoglycopeptide that inhibits cell proliferation and
metabolism (18,16,27,28). The growth inhibitor has been
isolated by treating cerebral cortex cells with dilute
protease. The released inhibitor was then purified based
on charge, carbohydrate composition, size, and
hydrophobicity utilizing HPLC techniques (26). The
isolated sialoglycopeptide growth inhibitor has a molecular
weight of 18 kD, a pi of 3, and when bound to its receptor
on the surface of target cells, inhibits cell growth and
metabolism in a wide variety of cell lines (2,25).
Examination of the growth inhibitor's binding to target
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cells suggested that cell surface interaction was
sufficient to alter cell metabolism <25). Additionally,
results of testing the interaction of the slaloglycopept ide
with growth factors such as TPA and EGF, indicated that the
sialoglycopept ide acted as an antagonist influencing early
events In the signal transduction mechanism of TPA
mitogenesis (1,5). Further kinetic studies of the
antiprolific activity of the s ialoglycopept ide revealed
that the inhibitor may influence Ca + ion fluxes of target
cells. This was demonstrated using the calcium lonophore
A23187 which antagonized the biological activity of the
sialoglycopept ide while monensin, a sodium ionophore, had
no inhibitory activity (26).
To investigate further the structure and biological
activity of the s ialoglycopept ide growth inhibitor, we have
developed monoclonal antibodies against the inhibitor.
Monoclonal antibodies have been established as practical
tools for use in a variety of laboratories. Predominantly,
they have been utilized for the purification and
Identification of specific proteins (12,14,29). Recent
investigations, however, have also seen the use of
monoclonal antibodies in sophisticated techniques such as
molecular probes to localize molecules on cell surfaces (6)
and immunotherapy of cancer (17). We have produced three
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monoclonal antibodies, G4, G8 and F10, to the
slaloglycopept ide
. In this report we present evidence that
the three monoclonal antibodies belong to the IgGl
subclass, are directed against the polypeptide backbone of
the inhibitor, can neutralize the inhibitor's biological
activity, bind to individual antigenic determinants, and
are unique to the slaloglycopept ide as they do not
recognize determinants on other growth inhibitors such as
fibroblast growth regulator and p" -transforming growth
factor.
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MATERIALS AND METHODS
PURIFICATION OF THE SI ALOGLYCOPEPTIDE: The
sialoglycopept ide was prepared as described by Klnders e.£
al. (18) with the modifications of Sharlfl £t §1. (27).
Briefly, the cerebral cortex cells from freshly killed
cattle were treated at 37° C for 20 mln with a pronase
solution containing 0.02 units of prote lnase/ml bovine
cells. The cells were removed by centrlfugatlon and the
macromolecules were precipitated with ethanol and extracted
with chlorof orm/methanol . Extracted material was then
purified by DEAE Ion exchange, wheat-germ agglutinin lectin
affinity chromatography, gel permeation, and hydroxyapat i te
HPLC (27). The purified sialoglycopept lde is an 18 kD
protein based on SDS-PAGE analysis and has an isoelectric
point of 3.0 (27).
DEGLYC08YLATI0N OF INHIBITOR: Deglycosylation of the
sialoglycopept ide was carried out essentially by the
methods of Manjunath ££ al- (23). Lyophllized
sialoglycopept ide was dissolved in trif luoracet ic acid
containing 1.0% (v/v) ethyl methyl sulfide. A stream of
hydrogen bromide gas was passed through the acidic solution
of sialoglycopeptide for 2 hr and then evaporated to
dryness under a stream of nitrogen. The deglycosylated
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sialoglycopeptlde was resuspended In distilled water and
dialyzed against water to remove residual acid. Following
dialysis, the deglycosylated sialoglycopeptlde was
concentrated by lyophi 1 izat ion, resuspended in PBS buffer,
and passed through a [,* B2ly.Ebe.rn.us. lectin affinity column
where the unbound fractions were collected and assayed for
inhibitory activity.
PRODUCTION OF HYBRIDOMAS: Non- immunized Balb/c mice were
bled and the sera was tested by solid phase radiolmmune
assay for the presence of cross reacting antibodies to the
sialoglycopeptlde antigen. Following preimmune screening,
non-reacting mice were injected intraper i toneal ly with
approximately 5 ug of purified sialoglycopeptlde in
Fruend's complete adjuvant and reinjected similarly one
month later with an equal amount of antigen. Ten days
after the second injection, mice were bled and the sera
were screened by solid phase radiolmmune assay for antibody
production to the sialoglycopept ide . Positive producers
were boosted intervenously with 1 ug of sialoglycopeptlde
in complete adjuvant and 5 days later were sacrificed for
the production of hybrldomas.
Essentially, hybridoma production and cell maintenance
were performed as described by Fazekas de St. Groth and
Scheidegger (8). Antigen stimulated splenocytes or the
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non-secreting Balb/c myeloma cell line P3-X63-Ag8.6.5.
3
(Ag8) (American Type Culture Collection, Rockville, MD)
were centrifuged at 350 x g and resuspended in serum-free
Dulbecco's modified Eagle medium, recentr if uged at 350 x g
and counted. Cell viability was determined by Trypan blue
exclusion and viable splenocytes and Ag8 myeloma cells were
mixed at a ratio of 1:2, respectively, and pelleted by slow
speed centri f ugat ion. The supernatant fluid was removed
and 1 ml of a 50% (v/v) polyethylene glycol 4000 solution
in DMEM, with 5% (v/v) dimethylsul f ox ide , was slowly added
to the pellet with constant mixing. Cells were then
concentrated by centr i f ugat ion at 100 x g for 6 min to
enhance fusion. The cell pellet was resuspended in serum-
free DMEM, recentr if uged and then the cells were
resuspended in selective hypoxanthine, aminopterln, and
thymidine medium (HAT) (20). Hybridomas were plated at 1 x
10 5 cells/well over a macrophage feeder layer and
maintained with additions of fresh HAT medium every three
days to the culture wells. Culture wells producing anti-
sialoglycopept ide antibody, as determined by solid phase
radioimmune assay, were cloned by limiting dilution and
then expanded to increase production of monoclonal
ant ibody
.
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SOLID PHASE RADIOIMMUNE ASSAY: The solid phase radlolmmune
assay was carried out as described by Tsu and Herzenberg
(31) with slight modifications. 1 ug/well goat anti-mouse
immunoglobulins [IgM, IgG, and IgA] (Cooper Biomedical,
Malvern, PA) in 0.005 M phosphate buffered saline, pH 7.2
(50 ul/well) were absorbed to Immulon 1 Removawells
(Dynatech, Alexandria, VA) overnight at 4° C. Assay wells
were washed three times with 0.05% (v/v) Tween 20 (Sigma
Chemical Co., St. Louis, MO) in phosphate buffered saline
(washing solution). Non-specific binding sites were
blocked with 1% (w/v) egg ovalbumin (Sigma Chemical Co.)
solution at room temperature for 4 hr. Wells were again
washed with washing solution and 50 ul of either purified
monoclonal antibody or cell culture supernatant containing
the monoclonal antibody were added to each well. Assays
were incubated overnight at 4° C, washed, and again
incubated overnight at 4 ° C with 50,000 cpm/well of
radiolabeled slaloglycopept lde . All antigen dilutions were
made in blocking solution and after the final incubation,
each well was again washed three times and the bound
radioactivity determined.
PURIFICATION OF MONOCLONAL ANTIBODY: Hybridoma culture
supernatant was passed through a Cibracon blue affinity
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column (Bethesda Research Laboratories, Gaithersburg, MD).
Eluent containing the monoclonal antibody, as determined by
spectrophotometry, was collected and the immunoglobulins in
the fluid from the Cibracon blue column were then
precipitated with a 40% (v/v) ammonium sulfate solution
overnight at 4° C. The precipitated IgG fraction was then
pelleted by centr i f ugat ion at 5,000 rpm for 10 min and
resuspended with phosphate buffered saline. Monoclonal
antibody concentration was obtained by Coomasie blue
protein determination.
RADIOIODINATION OF PROTEINS: Proteins were radioiodinated
by the chloramine T method of Greenwood ££ §1. (10) with
the following modifications. Proteins were incubated with
I and chloramine T and then the reaction was quenched
with 200 ul of a saturated tyrosine solution (3). No
reducing agent was used. The free 125 I was separated from
the proteins by gel filtration, and after dialysis of the
radioiodinated sample against 0.1 M KI overnight, the
radiolabeled proteins were dialyzed extensively against
phosphate buffered saline.
SIZE-EXCLUSION HPLC: The s ialogl ycopept ide and its
autohydrolyzed peptide fragments were purified by HPLC
using the methods described by Sharif i e.£ a,l« (27).
Briefly, biologically active fractions were injected into a
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G3000 TSK column equilibrated with 0.2 M potassium
phosphate (pH 6.5) and the flow rate was 1.0 ml/mln.
Samples from the column were dlalyzed against delonlzed
water, lyophillzed, and tested for biological inhibitory
activity and protein content. Fractions with biological
activity were pooled and kept frozen at -80° C.
PROTEIN SYNTHESIS INHIBITION ASSAY: Methods to determine
materials that can inhibit protein synthesis were described
by Kinders et al. (19). 25 ul of material in Dulbecco's
modified Eagle medium (DMEM) /N-2-hydroxy-ethylpiperaz ine-
N'-2-ethanesulfonlc acid (HEPES) was placed in 13 x 100 mm
tubes, 5 x 10 3T3 cells in 100 ul of DMEM/HEPES <pH 7.1)
were added, and the tubes were covered and incubated at 37°
C for 45 min. Following incubation, 2.0 uCi of t 35 Sl
methionine in 10 ul of DMEM/HEPES (pH 7.1) was added and
the tubes were re incubated at 37 ° C for 1 hr. Cells were
then pelleted by centr i f ugat ion and lysed with deionized
water. Macromolecules were precipitated by addition of an
equal volume of 20% ice-cold trichloroacetic acid. The
precipitates were collected by centr i f ugat ion and the
supernatant discarded. The pellet was resolubil lzed in 0.1
M NaOH and reprecipitated with 20% trichloroacetic acid and
the macromolecules were collected by centr i fugat ion. The
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precipitated material was again resuspended in distilled
water and resolubi 1 ized in 0.1 M NaOH. An aliquot of the
resolubil ized material was taken for liquid scintillation
counting.
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RESULTS
Conditioned medium from hybrldoma cultures producing
ant i-sialoglycopept ide monoclonal antibodies were titrated
against the sialoglycopept ide, utilizing a solid phase
radioimmune assay, to determine an approximate antibody
avidity. From data shown in Fig. 1, the monoclonal
antibody G8 sustained an antibody titer of 9600,
signifying the midpoint between the maximum and minimum
radioactive cpm of bound sialoglycopept ide detected.
Results seen in Fig. 1 were also representative of the
approximate antibody titer of the monoclonal antibodies G4
and F10 as well
.
After determining the avidity of the monoclonal
antibodies, it was Imperative to lsotype them before
carrying out further experiments. Established mouse
immunization protocols designed to elicit antibody
responses typically result in secondary immune responses
from which high titers of IgG antibodies are produced
having a high affinity for the immunogen. Therefore, we
suspected that the ant i-s laloglycopept ide monoclonal
antibodies were IgG antibodies. Utilizing the anti-mouse
antibodies of several classes and subclasses provided by a
commercial isotyping kit, we prepared an ELISA assay.
Visual inspection of the assay wells revealed, correlating
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with antibody titer, that again the three monoclonal
antibodies were similar as they were all of the IgGl
subclass (Table 1). Determination of monoclonal antibody
subclass was accomplished by comparing experimental assay
wells to positive control wells containing all classes of
mouse antibodies (normal mouse serum) and negative control
wells without second antibody.
Upon identification of the subclass of the monoclonal
antibodies, we were then interested in determining if the
monoclonal antibodies were directed towards the polypeptide
or the oligosaccharide portions of the s ialoglycopept ide
.
The purified s ialoglycopept ide growth inhibitor is an 18 kD
glycoprotein which has sidechains of low molecular weight
carbohydrate moeities but the biologically active portion
of this molecule is the polypeptide backbone (24). To
determine if the monoclonal antibodies are directed against
the biologically active polypeptide backbone, we performed
a competitive solid phase radioimmune assay. The
competitive solid phase radioimmune assay enabled the
detection of monoclonal antibody binding to the polypeptide
portion of the sialoglycopept ide by evaluating the binding
competition produced by adding deglycosylated and
radiolabeled native sialoglycopept ide simultaneously to the
41
solid phase assay. Results shown In Table 1 Indicate that
the three ant 1-slaloglycopept lde monoclonal antibodies
bound to the biologically active polypeptide backbone of
the growth inhibitor. Bound radiolabeled glycosylated
s ialoglycopept ide is shown to be reduced 65% by 16 ng of
deglycosylated s ialoglycopept ide when simultaneously
Incubated in assay wells containing the monoclonal
antibody, G4. Similar results were obtained with G8 and
F10.
The ability of the three monoclonal antibodies to
neutralize the inhibitory action of the s ialoglycopept ide
was tested by incubating each of the monoclonal antibodies
with sialoglycopept ide overnight at 4°C. A constant molar
concentration (3 inhibitory units) of growth Inhibitor was
incubated with an equal or Increasing molar concentration
of purified monoclonal antibody. The solution containing
the antibody-antigen complex was then incorporated into an
assay to detect protein synthesis inhibition of Swiss 3T3
fibroblasts. The monoclonal antibodies G8 and F10 were
able to neutralize 100% of the biological activity of the
sialoglycopeptide with a 1:10 or 1:1 molar equivalent,
respectively (Table 2). Opposlngly, G4 could only achieve
46% neutralization at a 100 fold molar excess of G4 to the
growth inhibitor. Control assays revealed that without
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preincubation of the antibodies with the sialoglycopept ide,
the antibodies did not significantly affect the biological
activity of the inhibitor (data not shown). Although, in
experiments previously described in this report all three
monoclonal antibodies reacted to the polypeptide backbone
of the sialoglycopept ide
, G4 appeared to be a distinct
monoclonal antibody as determined by neutralization assay
data.
An interesting property of the purified
sialoglycopept ide is that it carries an unique protease
activity as well as inhibitory properties. As determined
by Sobieski et al.. (30), this protease activity is not
responsible for the biological inhibitory activity.
Because of the associated protease activity, the growth
inhibitor molecule is subject to autohydrol izat ion at 37°C
and this provided a means to further characterize the three
monoclonal antibodies. When purified to homogeneity, the
sialoglycopept ide inhibitor elutes from gel permeation HPLC
as a single peak (Fig. 2). However, when incubated at 37°C
for either 1 hr or 24 hr, four discrete peaks elute from
the HPLC column (Fig. 3). Three of these peaks had
molecular weights of 1G kD (I), 10 kD (III), and < 4 kD
(IV) using HPLC molecular weight control standards.
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Unfortunately, peak II could not be separated sufficiently
from peak I, therefore, It was not used for further
experiments.
Utilizing the polypeptide fragments associated with
peaks, I, III, IV, and the native sialoglycopeptide, a
competitive radioimmune assay was performed to detect
fragment binding by the three monoclonal antibodies. Data
from Figs. 4 and 5 showed that all three monoclonal
antibodies bound to fragments I and III. However, G8
produced a binding competition between fragment I and
radiolabeled sialoglycopeptide which was equivalent to the
competition produced by G8 between labeled and non-labeled
native sialoglycopeptide. This competition was not evident
with G4 or F10. Accordingly, all three monoclonal
antibodies also bound to fragment III but did not produce
the binding competition that was seen between G8 and
fragment I. Conclusions drawn from this information
established that at least epitopes for all three monoclonal
antibodies are located on fragments I and III of the
sialoglycopeptide. The lowest molecular weight fragment
resulting from autohydrolysls of the sialoglycopeptide,
fragment IV, was not bound by any of the monoclonal
antibodies (data not shown).
Aside from characterization of the anti-
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sialoglycopept ide monoclonal antibodies, G8 was used as a
tool to compare the s ialoglycopept ide with other growth
regulators that are presently being studied. A limited
supply of growth regulators allowed for the use on only one
monoclonal antibody for this experiment. In this
experiment fibroblast growth regulator (FGR) and P -
transforming growth factor (TGF) were used because they
have biological properties similar to that of the
sialoglycopept ide. This suggested that the
sialoglycopept ide might contain regions in its amino acid
sequence that are shared with these other growth
regulators. However, as seen in Fig. 6, G8 did not
recognize epitopes on either FGR or TGF. In a competitive
solid phase radioimmune assay, radiolabeled
sialoglycopeptide and either TGF and FGR were
simultaneously added in equimolar concentrations to assay
wells containing bound monoclonal antibody. Neither of the
growth regulators could compete with the sialoglycopeptide
for the antibody's binding sites even at concentrations to
assay wells containing bound monoclonal antibody. Neither
of the growth regulators could compete with the
sialoglycopeptide for the antibody's binding sites even at
concentrations of 100 fold excess of TGF and FGR.
Therefore, it can be concluded that at least the amino acid
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sequence acting as the epitope for G8 Is different from the
other known growth inhibitors. These data confirm that the
sialoglycopept ide is not similar to either of these
previously identified growth regulatory molecules.
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DISCUSSION
Three monoclonal antibodies specific for a
sialoglycopept ide cell growth inhibitor, G4, G8, and F10
have been isolated and purified. These monoclonal
antibodies were isotyped using a standard ELISA assay
utilizing ant I-lmmunoglobul in typing antisera and were
shown to be IgGl antibodies. This was not an unusual
finding as the IgGl subclass makes up 70% of the IgG
proteins elicited by an immune response (7). The IgG
antibody is also a very stable molecule with a high
affinity for its specific ligand (7). This enabled
indefinite storage of the antibodies for future experiments
and will be beneficial for future use In affinity
chromatography purification of the sialoglycopeptide .
Further characterization of these monoclonal
antibodies was carried out using a competitive solid phase
radioimmune assay to establish the approximate location of
the antibody epitopes on the sialoglycopeptide molecule.
The competitive solid phase radioimmune assay has been used
successfully in similar studies characterizing antibodies
directed against creatine kinase and lactate dehydrogenase
and has been determined to be more sensitive than
traditional ELISA assays (32). Therefore, we utilized this
assay to compete glycosylated native sialoglycopeptide with
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its deglycosylated counterpart (27). It was possible that
the monoclonal antibodies were specific for one of the
carbohydrate sidechains associated with the native
sialoglycopeptide and this would render the antibodies
unsuitable for future investigations such as amino acid
sequencing of the growth inhibitor. However, data from
this experiment allowed the conclusion that all three
monoclonal antibodies had epitopes located on the
biologically active polypeptide backbone of the
sialoglycopeptide (Table 1).
Initial characterization of the monoclonal antibodies,
thus far, indicated that the antibodies were of identical
subclass and were similar in their ability to bind to the
biologically active sialoglycopeptide. However, when the
growth inhibitor was autohydrolyzed and the fragments
separated by HPLC (Fig. 3), the monoclonal antibodies
appeared to bind the peptide fragments differently (Figs. 4
and 5). For example, G8 produced substantial competition
of binding between the native sialoglycopeptide and peptide
fragment I whereas G4 and F10, although having the ability
to bind fragment I, did not produce equal competition.
These data may reflect the possibility that the epitope for
G8 Is made more available to the antibody as a result of
the tertiary structure of fragment I. All three monoclonal
48
antibodies revealed similar competition of binding for
fragment III. Although the molecular weights of fragments
I and III are very close <1G and 10 kD, respectively), the
tertiary structure of fragment III may have left the G8
epitope less available for binding.
Apparent differences between monoclonal antibodies,
G4, G8, and F10 were again noted in studying the ability of
the antibodies to neutralize the biological activity of the
sialoglycopeptide
. Antibodies have previously been
utilized in neutralization assays of biologically active
molecules to identify proteins (4,14) and in experiments
neutralizing growth inhibitors for the purpose of
discriminating between antibodies (29). In our
neutralization studies G4 lacked the ability to block the
inhibitory properties of the sialoglycopeptide as compared
to G8 and F10 which abolished the activity (Table 2). G8
and FlO's neutralizing ability, and the knowledge that the
sialoglycopeptide does not need to be internalized to
produce a biological response (25), suggests that they may
be directed against antigenic determinants at or near the
inhibitor's receptor binding site. Opposingly, G4 which
binds to the biologically active sialoglycopeptide, as
previously discussed, may have an epitope distal to the
site of binding.
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Initial experiments utilizing the monoclonal
antibodies for other than characterization was to establish
the sialoglycopept ide as a novel growth inhibitor. Cell
growth inhibitors with biological properties similar to the
sialoglycopept ide have been reported (4,13). Two such
growth regulators, fibroblast growth regulator (FGR) (33)
and P -transforming growth factor (TGF) (22), were
incorporated into a competitive solid phase radioimmune
assay to detect similarities to the sialoglycopept ide .
Data from Fig. 6 indicated that the monoclonal antibody,
G8, would not bind to either FGR or TGF. Thus, the
sialoglycopept ide contains, at least, an unique amino acid
sequence which is acting as a determinant for G8. In
addition, Bascom e.t a.1. (1) have reported that FGR and TGF
do not competitively bind with the sialoglycopept ide for
its cell surface receptor. However, this does not imply
that homologies to FGR and TGF do not exist. Comparisons
to other growth inhibitors have not yet been completed, but
to date, it appears that the sialoglycopept ide is a novel
growth inhibitor.
Experiments have been initiated using the anti-
sialoglycopept ide monoclonal antibodies as aids in the
purification of the growth inhibitor by affinity
chromatography. Fab fragmentation of the monoclonals would
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also allow the probing of cell surfaces to detect the
slaloglycopept ide on a variety of established and primary
cell cultures. Aside from the practicality of the
monoclonal antibodies as laboratory tools, further
characterization of the antibodies would be useful. The
results of this study suggest that G4, G8, and F10 may be
directed against individual antigenic determinants.
Eventually, these antibodies may aid in the localization of
the specific amino acid sequence which is responsible for
the slaloglycopept ide's biological activity and enable the
growth inhibitor to be synthesized in the laboratory.
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Fig. 1. Antl-sialoglycopeptide monoclonal antibody
titration curves. Antibody titer of G4
(A), G8 (•) and F10 <) antibodies were
determined by solid phase radloimmune assay
as described in the materials and methods.
Following Initial absorption of goat anti-
mouse immunoglobulins to polystyrene wells,
serially diluted samples of each antibody were
added to the wells. 50,000 cpm radiolabeled
sialoglycopept ide was then incubated in each
well. After washing, bound radioactivity was
measured. Each assay was performed in triplicate
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Table 1. Isotyplng and binding of the monoclonal antibodies
to the biologically active sialoglycopeptide
.
a. Isotyplng was accomplished using a
commercial ELISA isotyping kit. Briefly,
polystyrene microtiter wells were coated with
goat anti-mouse immunoglobulins and Incubated
overnight at 4°C. Following, each experimental
assay received hybrldoma supernatant, anti-
immunoglobulins typing antisera, peroxidase
conjugated goat anti-rabbit IgG, and o-phenylene
diamine (a chromophore substrate), respectively.
Assay wells were repeatedly washed with phosphate
buffered saline and allowed to incubate at room
temperature for approximately 1 hr between each
antibody addition.
b. Deglycosylated sialoglycopeptide assay was
carried out using a solid phase competitive
radioimmune assay as described in the materials
and methods. Following initial plating of anti-
mouse immunoglobulins, assay wells received G4,
G8, or F10 monoclonal antibodies. Radiolabeled
glycosylated and increasing concentrations of
non-labeled deglycosylated sialoglycopeptide were
then added simultaneously. After final washes,
bound radioactivity was determined.
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Table 2. Neutralization of the biologically active
sialoglycopept lde using the monoclonal
antibodies. Following incubation of G4, G8 and
F10 monoclonal antibodies with the
sialoglycopept lde overnight at 4°C, the antibody-
ligand complexes were added to 3T3 cells. t 35 S3
methionine was then introduced into each assay
tube. Cells were pelleted, lysed, precipitated
with trichloroacetic acid and resolubll ized as
described in the materials and methods. Aliquots
of each assay were taken for liquid scintillation
counting and the percent protein synthesis
inhibition calculated. Control assays contained
only sialoglycopept ide.
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Fig. 2. Homogeneity of the sialoglycopept ide as defined
by gel permeation HPLC. Purified
sialoglycopeptide was applied to a gel
permeation HPLC column equilibrated with 0.2 M
phosphate buffer, pH 6.5. Flow rate of the
column was 1.0 ml/mln. The fractions at
approximately 10 min were tested for inhibition
of 3T3 cell protein synthesis.
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Fig. 3. Autohydrolyzed sialoglycopept lde as defined by
gel permeation HPLC. Briefly, purified
sialoglycopept lde was Incubated for 1(A) or 24(B)
hr at 37°C and subsequently applied to a HPLC gel
permeation column equilibrated with a 0.2 M
phosphate buffer, pH 6.5. Flow rate was 1.0
ml/mln. All fractions were tested for
Inhibitory activity.
75
- 2 <-
E
o
* CM O
(g.OlxWdD) punog 8P!4dadooX|6o|DjS-|fi2 ,
76
Fig. 4. Binding of the monoclonal antibodies to
slaloglycopeptlde fragment 1. Following
Initial plating of goat anti-mouse
immunoglobulins to microtiter wells, assays
received either G4 (A), G8 (•) or F10 <>
monoclonal antibody. After Incubation, wells
received 10 ng radiolabeled slaloglycopeptlde
and increasing concentrations of nonlabeled
fragment 1, simultaneously. Radioactivity was
measured following final washes of assay wells
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Fig. 5. Binding of the monoclonal antibodies to
slaloglycopeptlde fragment 3. Following Initial
plating of goat anti-mouse immunoglobulins to
microtiter wells, assays received either G4 (A),
G8 (•) or F10 <) monoclonal antibody. After
incubation, wells received 10 ng radiolabeled
sialoglycopeptide and increasing concentrations
of nonlabeled fragment 3, simultaneously. Radio-
activity was measured following final washes of
assay wells. Each assay was performed in
tripl icate
.
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Fig. 6. Comparison of the sialoglycopept ide to fibroblast
growth regulator <FGR) and B-transformlng growth
factor (TGF>. After initial coating of micro-
titer wells with goat anti-mouse immunoglobulins,
each assay well received monoclonal G8.
Following incubation, 2 ng (1 mole) radiolabeled
sialoglycopept ide and increasing molar concen-
trations of either FGR (O) or TGF (•) were added
simultaneously. Each assay was performed in
tripl icate
.
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ABSTRACT
Since the development of the first specific antibody
producing hybrid cells in 1975, monoclonal antibodies have
become sophisticated and very practical research tools that
are presently being employed by a large number of
biological research laboratories. This report attempts to
describe the advancements that have been made in monoclonal
antibody technology in the past decade and to discuss one
of the most recent utilizations of monoclonal antibodies,
cancer therapy.
Predominantly, however, monoclonal antibodies are used
as a method to purify and characterize specific biological
proteins. Our laboratory has isolated, from bovine
cerebral cortex cells, an 18 kD s ialoglycopept ide growth
regulator which inhibits cellular protein and DNA
synthesis. We have characterized three monoclonal
antibodies directed against this growth inhibitor which
will eventually enable the rapid purification of the
sialoglycopept ide or its parental molecule and allow for
the detection of the protein on a variety of cell surfaces.
Additionally, these monoclonal antibodies were useful in
demonstrating that the sialoglycopept ide is unique from
other presently studied growth regulators such as P -
transforming growth factor and fibroblast growth regulator
and can be depicted as a novel cell growth inhibitor.
